Over 4.6 million Americans left the individual health insurance market between June 2025 and June 2026, marking an 18% drop, the largest in a decade. This decline is driven by the expiration of enhanced premium tax credits, causing costs to double or triple for some. Insurers are responding with a proposed median premium increase of 15% for 2027, anticipating further departures and a riskier pool of insured individuals. This trend risks triggering a 'death spiral' where rising premiums push healthier people out, increasing costs for those who remain. The upcoming Open Enrollment Period will reveal if this cycle continues, with insurers closely watching the age and health profile of new enrollees.
The recent exodus of 4.6 million Americans from the health insurance market and a 15% rate hike provide context for Pluang's health sector data. For readers following health-sector US stocks, here is Pluang's market snapshot as of Oct 19, 2026 20:02 WIB: out of 150 stocks, 62 rose and 66 fell. Notably, CTXR gained 4.13% to USD 0.48 with a typical hold time of 17 days, while HRTX rose 2.49% to USD 0.37 and TWST increased 2.30% to USD 135.80, with hold times ranging from 17 to 36 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
